LRRC15/LIB[Biotin], His & Avi, Cynomolgus/Rhesus macaque
| $660.00 | |
| Z04380-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| $660.00 | |
| Z04380-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Species | Cynomolgus/Rhesus macaque | ||||||
| Protein Construction |
|
||||||
| Conjugate | Biotin | ||||||
| Purity | > 95% as determined by BisTris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 61.50 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 70-90 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized Anti-LRRC15 Antibody, hFc Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for LRRC15/LIB[Biotin], His & Avi, Cynomolgus/Rhesus macaque, His Tag with the EC50 of 75.9ng/ml determined by ELISA. »
The purity of LRRC15/LIB[Biotin], His & Avi, Cynomolgus/Rhesus macaque is greater than 95% as determined by SEC-HPLC. »
LRRC15/LIB[Biotin], His & Avi, Cynomolgus/Rhesus macaque on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | The chimeric protein binds in vitro and in vivo to a specific element upstream of LRRC15, leading to dramatic transcriptional activation. LRRC15 encodes a leucine-rich transmembrane protein, present at the leading edge of migrating cells, the expression of which in normal tissues is restricted to the invasive cytotrophoblast layer of the placenta; small interfering (siRNA)-mediated suppression of LRRC15 expression in breast cancer cells leads to abrogation of invasiveness in vitro. |
| Synonyms | LIB; LRRC15; EGM_11224 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.